|
|
Vol. 15.01 – 29 January, 2026
|
|
|
|
|
|
|
Researchers profiled lung tissue by single-nucleus RNA sequencing from 141 study participants and identified shifts in cell composition and emergent cell states to investigate chronic obstructive pulmonary disease heterogeneity. [Nature Genetics]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators characterized the changing cellular, transcriptional, and genomic landscape of human lung aging using single-cell RNA sequencing.
[Nature Communications]
|
|
|
|
|
|
To investigate the alterations in fibroblasts, particularly the molecular programs driving this profibrotic evolution in the aging lung, scientists isolated senescent lung fibroblasts from aged mice.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
The authors demonstrated that macrophage-derived apoptotic body delivery system co-loaded with sodium arsenite (SA) and N-acetylcysteine (NAC) represents an effective therapeutic strategy for idiopathic pulmonary fibrosis.
[Journal of Nanobiotechnology]
|
|
|
|
|
|
Researchers uncovered an epigenetic mechanism restraining disease-driving macrophage states and suggested the lysine-specific demethylase 7 A (KDM7A)-toll-like receptor 8 axis as a potential therapeutic target in fibrotic disorders.
[Communications Biology]
|
|
|
|
|
|
Investigators aimed to assess estrogen sulfotransferase (SULT1E1) expression and underlying mechanisms in chronic obstructive pulmonary disease (COPD) pathogenesis. [Scientific Reports]
|
|
|
|
|
|
|
|
Researchers revealed a novel mechanism which interconnects replication stress induced by oncogenic p53 to its stabilization and ability to generate chromosomal aberration in lung cancer cells that both accelerate tumor growth and serve as a targetable therapeutic vulnerability.
[Cell Death & Disease]
|
|
|
|
|
|
Investigators demonstrated that EGFR-mutant SCLC is composed of mixed cell states with distinct therapeutic vulnerabilities and offer a therapeutic strategy to target tumor heterogeneity in highly plastic and treatment-resistant malignancies.
[JCI Insight]
|
|
|
|
|
|
Scientists investigated the expression and prognostic value of miR-323b-5p in NSCLC patients, and to clarify the mechanisms of miR-323b-5p and interleukin 1α (IL1A) on the proliferation and cell cycle of NSCLC cells. [Discover Oncology]
|
|
|
|
|
|
|
|
The authors summarize the current molecular insights into lung carcinogenesis in lung cancer with idiopathic pulmonary fibrosis and present findings from recent comprehensive genetic analysis. [International Journal of Clinical Oncology]
|
|
|
|
|
|
|
|
Summit Therapeutics, Inc. announced that the FDA has accepted for filing Summit’s BLA seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC post-tyrosine kinase inhibitor (TKI) therapy. [Summit Therapeutics, Inc.]
|
|
|
|
|
|
|
|
March 7-10, 2026 Playa Mujeres, Mexico
|
|
|
|
|
|
|
|
|
|
|
University of Illinois at Chicago – Chicago, Illinois, United States
|
|
|
|
|
|
|
University of Texas Health Science Center – Houston, Texas, United States
|
|
|
|
|
|
|
Temple University – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
|
|
Princeton University – Princeton, New Jersey, United States
|
|
|
|
|
|